A COMPARISON OF AMERICAN JOINT COMMITTEE ON CANCER PATHOLOGIC STAGE T3a VERSUS T3b UROTHELIAL CANCER: ANALYSIS OF PATIENT OUTCOMES

2008 ◽  
Vol 179 (4S) ◽  
pp. 546-546
Author(s):  
Kelly J Boudreaux ◽  
Sam S Chang ◽  
William T Lowrance ◽  
Jon A Rumohr ◽  
Daniel A Barocas ◽  
...  
Keyword(s):  
Patient Outcomes ◽  
Urothelial Cancer ◽  
Pathologic Stage ◽  
American Joint Committee

A COMPARISON OF AMERICAN JOINT COMMITTEE ON CANCER PATHOLOGIC STAGE T2a VERSUS T2b UROTHELIAL CANCER: ANALYSIS OF PATIENT OUTCOMES IN ORGAN CONFINED BLADDER CANCER

2008 ◽  
Vol 179 (4S) ◽  
pp. 579-579
Author(s):  
Kelly J Boudreaux ◽  
Peter E Clark ◽  
William T Lowrance ◽  
Jon A Rumohr ◽  
Daniel A Barocas ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Patient Outcomes ◽  
Urothelial Cancer ◽  
Pathologic Stage ◽  
American Joint Committee

scholarly journals Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma: Analysis of patient outcomes

Cancer ◽  
2009 ◽  
Vol 115 (4) ◽  
pp. 770-775 ◽  
Author(s):  
Kelly J. Boudreaux ◽  
Sam S. Chang ◽  
William T. Lowrance ◽  
Jon A. Rumohr ◽  
Daniel A. Barocas ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Patient Outcomes ◽  
Pathologic Stage ◽  
American Joint Committee

Comparison of American Joint Committee on Cancer Pathological Stage T2a Versus T2b Urothelial Carcinoma: Analysis of Patient Outcomes in Organ Confined Bladder Cancer

2009 ◽  
Vol 181 (2) ◽  
pp. 540-546 ◽  
Author(s):  
Kelly J. Boudreaux ◽  
Peter E. Clark ◽  
William T. Lowrance ◽  
Jon A. Rumohr ◽  
Daniel A. Barocas ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urothelial Carcinoma ◽  
Patient Outcomes ◽  
Pathological Stage ◽  
American Joint Committee

scholarly journals Neoadjuvant chemotherapy (NC) should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer (MIUC) of the bladder – A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process

2013 ◽  
Vol 7 (9-10) ◽  
pp. 312 ◽  
Author(s):  
Jo-An Seah ◽  
Srikala Sridhar ◽  
Lori Wood ◽  
Normand Blais ◽  
Scott North ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Patient Outcomes ◽  
Urothelial Cancer ◽  
Consensus Statement ◽  
Urologic Oncology ◽  
Canadian Association ◽  
Medical Oncologists ◽  
Cancer Of The Bladder ◽  
Muscle Invasive ◽  
Improve Patient

Neoadjuvant chemotherapy (NC) improves overall survival inpatients with resectable muscle-invasive urothelial cancer of the bladder (MIBC). However uptake of NC in Canada is disappointingly low. Following a detailed literature review and in consultation with urologic oncology, the Canadian Association of Genitourinary Medical Oncologists (CAGMO) has developed a consensus statement for the use of NC in MIBC. Our primary goal is to increase the uptake of NC for MIBC in Canada and improve patient outcomes.

scholarly journals Biomarkers of immune checkpoint inhibitor efficacy in cancer

2019 ◽  
Vol 27 (S2) ◽  
Author(s):  
D. E. Meyers ◽  
S. Banerji
Keyword(s):  
Patient Outcomes ◽  
Immune Checkpoint ◽  
Immune Modulation ◽  
Urothelial Cancer ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Cell Cancer ◽  
Small Cell Lung ◽  
Cell Mediated Immune Response

Immune checkpoint inhibitor–based therapies that target ctla-4, PD-1, or the PD-1 ligand PD-L1 have received approval in Canada and many parts of the world for the treatment of melanoma, renal cell cancer, urothelial cancer, classical Hodgkin lymphoma, and non-small-cell lung cancer. However only a small proportion of patients derive long-term clinical benefit. Here, we describe the biomarkers associated with the complex relationship between tumour-related immune stimulus, T cell–mediated immune response, and immune modulation of the microenvironment that can help to predict improved patient outcomes.

scholarly journals Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer

2021 ◽  
Vol 9 (7) ◽  
pp. e002552
Author(s):  
Matthew D Galsky ◽  
Arjun V Balar ◽  
Peter C Black ◽  
Matthew T Campbell ◽  
Gail S Dykstra ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Patient Outcomes ◽  
Clinical Practice Guideline ◽  
Practice Guideline ◽  
Urothelial Cancer ◽  
Diagnostic Testing ◽  
Care Providers ◽  
Immunotherapy Of Cancer ◽  
Selection Of

A number of immunotherapies have been developed and adopted for the treatment of urothelial cancer (encompassing cancers arising from the bladder, urethra, or renal pelvis). For these immunotherapies to positively impact patient outcomes, optimal selection of agents and treatment scheduling, especially in conjunction with existing treatment paradigms, is paramount. Immunotherapies also warrant specific and unique considerations regarding patient management, emphasizing both the prompt identification and treatment of potential toxicities. In order to address these issues, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts in the field of immunotherapy for urothelial cancer. The expert panel developed this clinical practice guideline (CPG) to inform healthcare professionals on important aspects of immunotherapeutic treatment for urothelial cancer, including diagnostic testing, treatment planning, immune-related adverse events (irAEs), and patient quality of life (QOL) considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers treating patients with urothelial cancer.

Sign in / Sign up

Export Citation Format

Share Document